ArticleCell cycle (Georgetown, Tex.)2013
Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.
Article in Cell cycle (Georgetown, Tex.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- PTPN18 functions as a tumor suppressor in breast cancer by negatively regulating cyclin E.International journal of oncology · 2026Article
- Article
- Large-scale phenogenomic analysis of human cancers uncovers frequent alterations affecting SMC5/6 complex components in breast cancer.NAR cancer · 2023Article
- Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.NPJ breast cancer · 2021Article
- Article
- Article
- Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia.Leukemia · 2020Article
- Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.Nature communications · 2019Article
- Prognostic Values ofJournal of Cancer · 2018Article
- Regulation of cyclin E1 expression in human pluripotent stem cells and derived neural progeny.Cell cycle (Georgetown, Tex.) · 2018Article
- p53-dependent up-regulation of CDKN1A and down-regulation of CCNE2 in response to beryllium.Cell proliferation · 2016Article
- Combinatorial PX-866 and Raloxifene Decrease Rb Phosphorylation, Cyclin E2 Transcription, and Proliferation of MCF-7 Breast Cancer Cells.Journal of cellular biochemistry · 2016Article
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.Cancer research · 2016Article
- MicroRNA-27b Enhances the Hepatic Regenerative Properties of Adipose-Derived Mesenchymal Stem Cells.Molecular therapy. Nucleic acids · 2016Article
- AKAP95 promotes cell cycle progression via interactions with cyclin E and low molecular weight cyclin E.American journal of translational research · 2016Article
- A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness.Oncotarget · 2015Article
- Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells.Cell division · 2015Article
- Aberrant regulation of FBW7 in cancer.Oncotarget · 2014Review
- Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle.Cell cycle (Georgetown, Tex.) · 2014Article
- Differences in regulation and function of E-cyclins in human cancer cells.Cell cycle (Georgetown, Tex.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclin E1 is expressed at the G 1/S phase transition of the cell cycle to drive the initiation of DNA replication and is degraded during S/G2M. Deregulation of its periodic degradation is observed in cancer and is associated with increased proliferation and genomic instability. We identify that in cancer cells, unlike normal cells, the closely related protein cyclin E2 is expressed predominantly in S phase, concurrent with DNA replication. This occurs at least in part because the ubiquitin ligase component that is responsible for cyclin E1 downregulation in S phase, Fbw7, fails to effectively target cyclin E2 for proteosomal degradation. The distinct cell cycle expression of the two E-type cyclins in cancer cells has implications for their roles in genomic instability and proliferation and may explain their associations with different signatures of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.